Joshua K. Ochieng - Concepedia

Author

Joshua K. Ochieng

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Joshua K. Ochieng, Joshua Kapere Ochieng, Joshua Ochieng, Joshua Ochieng Kapere

Publications

416

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Erasmus MC - Sophia Children’s Hospital The University of Texas Health Science Center at Houston Erasmus University Rotterdam Erasmus MC

About

Joshua K. Ochieng is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	210
2	Cell Biology	5	5	186
3	Cellular Physiology	2	2	108
4	Immunology	1	1	14
5	Pharmacology	1	1	24

Joshua K. Ochieng

Publications

393

Citations

H-Index

Page 1

	Year	Citations
Sox2 Regulates the Emergence of Lung Basal Cells by Directly Activating the Transcription of <i>Trp63</i> Joshua K. Ochieng, Kim Schilders, Heleen Kool, American Journal of Respiratory Cell and Molecular Biology Lung InflammationMolecular RegulationGeneticsOrgan DevelopmentCell Specialization	2014	94
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers David H. Peng, B. Leticia Rodriguez, Lixia Diao, Nature Communications	2021	64
Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development Warapen Treekitkarnmongkol, Maya Hassane, Ansam Sinjab, American Journal of Respiratory and Critical Care Medicine	2020	46
Hypoxia Inducible Factor 3α Plays a Critical Role in Alveolarization and Distal Epithelial Cell Differentiation during Mouse Lung Development Yadi Huang, Joshua K. Ochieng, Marjon Buscop-van Kempen, PLoS ONE Acute Lung InjuryLung InflammationPulmonary Alveolar ProteinosisOxidative StressTranscriptional Regulation	2013	35
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC Jessica Konen, B. Leticia Rodriguez, Aparna Padhye, Cancer Research	2021	30
MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs Joshua K. Ochieng, Samrat T. Kundu, Rakhee Bajaj, Oncogene Nsclc MetastasisJnk-dependent ActivationSignal TransductionSignaling PathwayMedicine	2020	28
Development of <i>Kras</i> mutant lung adenocarcinoma in mice with knockout of the airway lineage‐specific gene <scp><i>G</i></scp><i>prc5a</i> Junya Fujimoto, Sayuri Nunomura‐Nakamura, Yihua Liu, International Journal of Cancer	2017	27
Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial Matthew T. Campbell, Vania Balderrama-Brondani, Camilo Jiménez, The Lancet Oncology OncologyMetronomic TherapyPharmacologyCabozantinib MonotherapyPharmacotherapy	2024	24
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance B. Leticia Rodriguez, Limo Chen, Yanli Li, Frontiers in Immunology	2023	16
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer Aparna Padhye, Jessica Konen, B. Leticia Rodriguez, JCI Insight Emt-mediated Tumor HeterogeneityCancer BiologyTumor BiologySustained ResponseRadiation Oncology	2021	15

Page 1